Santen Pharmaceutical Second Quarter 2025 Earnings: Beats Expectations

Simply Wall St

November 12, 2024

Santen Pharmaceutical (TSE:4536) Second Quarter 2025 Results

Key Financial Results

Revenue: JP¥71.6b (down 2.4% from 2Q 2024).
Net income: JP¥8.14b (down 8.2% from 2Q 2024).
Profit margin: 11% (in line with 2Q 2024).
EPS: JP¥23.21 (down from JP¥23.45 in 2Q 2024).

earnings-and-revenue-growth — TSE:4536 Earnings and Revenue Growth November 12th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Santen Pharmaceutical Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 2.4%. Earnings per share (EPS) also surpassed analyst estimates by 5.5%.

Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 4.5% growth forecast for the Pharmaceuticals industry in Japan.

Performance of the Japanese Pharmaceuticals industry.

The company's shares are down 5.0% from a week ago.

Risk Analysis

We should say that we've discovered 1 warning sign for Santen Pharmaceutical that you should be aware of before investing here.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.